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Purpose: To examine the positive predictive value (PPV) of International Classification 
version 10 (ICD-10) diagnosis codes for Coronavirus disease 2019 (COVID-19).
Patients and Methods: Medical record review of all patients assigned a diagnosis code of 
COVID-19 (DB342A or DB972A) at six Danish departments of infectious diseases from 
February 27 through May 4, 2020. Confirmed COVID-19 diagnosis was defined as either: 1) 
definite, a positive polymerase chain reaction (PCR) for severe acute respiratory syndrome 
Coronavirus 2 (SARS-CoV-2) on a respiratory sample combined with symptoms suggestive 
of COVID-19: 2) probable, clinical presentation of COVID-19 without detection of SARS- 
CoV-2 and no alternative diagnoses considered more likely; or 3) possible, clinical presenta-
tion of COVID-19 without detection of SARS-CoV-2, and the patient was discharged or 
deceased before further investigations were carried out. We computed the PPV with 95% 
confidence intervals (CI) as the number of patients with confirmed (i.e., definite, probable, 
and possible) COVID-19 divided by the number of patients assigned a diagnosis code for 
COVID-19.
Results: The study included 710 patients with a median age of 61 years (interquartile range 
[IQR] 47–74) and 285/710 (40%) were female. COVID-19 was confirmed in 706/710 (99%) 
with 705/710 (99%) categorized as definite, 1/710 (0.1%) as probable, and 0 patients as 
possible COVID-19. The diagnosis was disproven in 4/710 (0.6%) patients who were 
hospitalized due to bacterial pneumonia (n = 2), influenza (n = 1), and urinary tract infection 
(n = 1). The overall PPV for COVID-19 was 99% (95% CI 99–100) and remained 
consistently high among all subgroups including sex, age groups, calendar period, and 
stratified by diagnosis code and department of infectious diseases (range 97–100%).
Conclusion: The overall PPV of diagnosis codes for COVID-19 in Denmark was high and 
may be suitable for future registry-based prognosis studies of COVID-19.
Keywords: Coronavirus disease 2019; COVID-19, SARS-CoV-2, diagnosis codes, ICD-10, 
positive predictive value; PPV, validation, epidemiology
Plain-Language Summary
We reviewed the medical records of 710 patients admitted at six departments of 
infectious diseases in Danish hospitals from February 27 through May 4, 2020 
with an ICD-10 diagnosis code of Coronavirus disease (COVID-19) and found 
an overall positive predictive value (PPV) of 99%. The results were consistent 
across different diagnosis codes for COVID-19, age groups, sex, calendar 
period, and departments of infectious diseases. These results are important for 
ensuring the validity of studies using ICD-10 diagnosis codes to identify 
COVID-19 patients.
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Introduction
COVID-19 is a potentially life-threatening infection for aging 
and other vulnerable populations.1–4 Health care databases 
allow researchers to effectively explore both common and 
rare associations in large populations,5–10 and may be valuable 
for long-term monitoring of efficiency and safety of treat-
ments and vaccines for COVID-19 outside the settings of 
randomized controlled trials. In addition, the epidemiological 
characteristics of COVID-19 are dynamic and rapidly change 
within and between countries as the pandemic evolves, and 
large health care registries may assist in quickly testing scien-
tific hypothesis in different settings.11–15 However, registry- 
based analyses using diagnosis codes require that the codes 
are of high quality and, thus far, the validity of ICD-10 codes 
for COVID-19 remains unclear. This study aimed to examine 
the PPV of the ICD-10 diagnosis codes for COVID-19 at 
departments of infectious diseases in Denmark.
Methods
Setting
In Denmark, medical care is tax-supported and free of 
charge at the point of delivery for all residents. A unique 
civil registration number assigned at birth or immigration 
allows for the unique identification of all Danish residents 
and unambiguous linkage between registries.7
Study Design and Study Population
This cross-sectional validation study was conducted by 
reviewing the medical records of all patients admitted with 
a first-time ICD-10 diagnosis code for COVID-19 (DB342A 
and DB972A) at departments of infectious diseases (and 
affiliated “pandemic departments”) at hospitals in Aalborg, 
Aarhus, Odense, Hillerød, and Copenhagen University 
Hospitals at Amager/Hvidovre and Rigshospitalet in 
Denmark from February 27 through May 4, 2020 
(Figure 1). Patients were identified by searches at each depart-
ment and the diagnosis codes correspond to those that are 
reported to the Danish National Patient Registry.9
Record Review and Definition of 
COVID-19
During medical record review, the admission date of first- 
time hospitalization for COVID-19 was used as index 
date. If patients were tested positive for Severe acute 
respiratory syndrome Coronavirus 2 (SARS-CoV-2) 
while hospitalized for other reasons, the date of test for 
SARS-CoV-2 was considered the index date. Next, a local 
investigator reviewed the medical records of all hospita-
lized patients assigned a COVID-19 diagnosis code at each 
center including doctor’s notes, laboratory results, micro-
biological analyses, imaging results as described by the 
Figure 1 Geographical distribution of the involved departments of infectious diseases in Denmark.
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hospital radiologist, and outcomes of the patients. In cases 
of doubt, categorizations of patients were resolved by 
discussion (JB and LO). The following definitions for 
COVID-19 were used: 
Definite COVID-19:
1. A positive polymerase chain reaction (PCR) for 
SARS-CoV-2 on a respiratory sample AND
2. A clinical presentation consistent with COVID-19, e. 
g., fever, sore throat, headache, nasal congestion, dyspnea, 
cough, nausea/vomiting, diarrhea, or myalgia. 
Probable COVID-19:
1. A clinical presentation consistent with COVID-19, i. 
e., any combination of fever, sore throat, headache, nasal 
congestion, dyspnea, cough, nausea/vomiting, diarrhea, 
and myalgia without detection of SARS-CoV-2 on 
a respiratory sample AND
2. No other pathogen detected, and no other medical 
condition was considered more likely. 
Possible COVID-19:
1. A clinical presentation consistent with COVID-19, i. 
e., any combination of fever, sore throat, headache, nasal 
congestion, dyspnea, cough, nausea/vomiting, diarrhea, 
and myalgia without detection of SARS-CoV-2 on 
a respiratory sample AND
2. The patient passed away or was discharged before 
further examinations had been performed including tests 
for SARS-CoV-2 and no other medical condition was 
considered more likely.
A diagnosis of COVID-19 was considered disproven if 
the patient did not fulfill any of the criteria listed above or 
had a confirmed alternative diagnosis.
Statistical Analyses
The PPV was calculated as the number of confirmed (i.e., 
definite, probable, and possible) COVID-19 cases divided 
by the number of patients assigned a diagnosis code of 
COVID-19 and using medical record review combined 
with results of PCR test for SARS-CoV-2 as reference. 
Using the exact binomial method, the PPV with 95% 
confidence intervals (CIs) was computed for patients 
with confirmed COVID-19 and by each category of defi-
nite, probable, and possible COVID-19. Additional ana-
lyses of the PPV for definite COVID-19 were conducted 
stratified by diagnosis code (DB342A or DB972A), age 
groups (0–40, 41–60, 61–80, 81+ years), sex, and calendar 
period (February 27 through March 31, and April 1 
through May 4). A post hoc analyses considering only 
definite diagnosis of COVID-19 for assessment of the 
PPV was also carried out. Categorical variables are pre-
sented as n/N (%) and continuous variables as medians 
with interquartile ranges (IQR).
Study data were collected and managed using REDCap 
electronic data capture tools hosted at North Denmark 
Region.16 Stata/MP® version 16 (StataCorp LLC, Texas) 
was used for all statistical analyses.
Ethical Considerations
The study was approved by the legal department at the 
North Denmark Region (record number 2020-045) and the 
Danish Board of Health (record number 31-1522-84). 
Patient consent or permission from an ethical committee 
is not required for this type of study in Denmark. Handling 
of data complied with relevant data protection and privacy 
regulations and was conducted in accordance with the 
Helsinki declaration.
Results
During the study period, a total of 710 patients were 
assigned a diagnosis code of COVID-19 (Table 1). The 
median age of patients was 61 years (IQR 47–74) and 
285/710 (40%) were females. Consistent with the overall 
development of the first wave of the pandemic in Denmark, 
542/710 (76%) patients were admitted early during the 
study period from February 27 through March 31, 2020.
A definite diagnosis of COVID-19 was observed in 705/ 
710 (99%) of patients, whereas the diagnosis was probable in 
1/710 (0.1%) and possible in 0 patients (Table 2). COVID-19 
was disproven in 4/710 (0.6%) patients, of which 2 were 
diagnosed with bacterial pneumonia (both had unknown 
pathogens and a clinical response to antibiotic therapy), 1 
with influenza, and 1 with a urinary tract infection.
Using both definite and probable diagnoses of COVID- 
19 as reference, the overall PPV for COVID-19 was 99% 
(95% CI 99–100) compared with 99% (95% CI 98–100) 
when using definite cases only (Table 3). The PPV was 
consistently high and ranged between 97% and 100% 
among all subgroups including sex, age groups, calendar 
period, and stratified by diagnosis code (DB342A and 
DB972A) and department of infectious diseases.
Discussion
This study observed a very high PPV of COVID-19 diag-
nosis codes for patients hospitalized in Denmark during 
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the first wave of the pandemic. The PPV ranged 97–100% 
in all examined subgroups including sex, age groups, and 
when stratified by diagnosis code.
The ongoing COVID-19 pandemic has led to an impress-
ive and unprecedented concerted effort of the entire global 
scientific community to rapidly explore the characteristics and 
treatment of this infection resulting in more than 100,000 
scientific publications on the topic in year 2020.17 Databases 
using ICD-10 diagnosis codes may be a valuable tool in 
expanding existing knowledge on COVID-19 by analyzing 
associations in large-scale populations.7–9,18 However, it 
remains pivotal that the accuracy of the used diagnosis codes 
is high. Using SARS-CoV-2 test positivity as reference, a large 
registry-based study from a US administrative all-payer repo-
sitory observed a PPV of 92% (95% CI 91–92) for ICD-10 
diagnosis codes for COVID-19.19 In general, the validity of 
diagnosis codes in Danish health care databases is high,9 and 
the results of the current study provide assurance of the useful-
ness of ICD-10 codes for COVID-19 in Denmark.
Previous registry-based studies have often utilised large 
microbiological databases of SARS-CoV-2 test-positive and 
test-negative persons to explore scientific hypothesis related 
to COVID-19. Strengths of this approach include capture of 
the majority of individuals with proven infection and identi-
fication of a potential control population (i.e., SARS-CoV-2 
test negative persons). However, a large proportion of SARS- 
CoV-2 positive individuals may have asymptomatic 
infection20–24 and the current study may thus allow research-
ers to combine clinical disease characteristics of COVID-19 
with documented SARS-CoV-2 infection.
This study has limitations. Selection bias may have been 
introduced by changes in testing strategies and management of 
COVID-19 patients. However, all patients admitted to hospital 
with symptoms of COVID-19 were tested for SARS-CoV-2 
throughout the study period in Denmark. In addition, the study 
included all patients assigned a diagnosis code of COVID-19 
at the participating centers representing different geographic 
regions of Denmark. Ascertainment bias, i.e., researchers 
examining the medical records were aware of the diagnosis 
code beforehand and may have favored confirmation of 
COVID-19 in cases of doubt, was mitigated by accessing all 
available information in the medical records and adhering to 
a strict a priori definition of confirmed COVID-19. Moreover, 
99% of patients had relevant symptoms and tested positive for 
SARS-CoV-2 by PCR of a respiratory sample. The study was 
not able to test the sensitivity, specificity, or completeness of 
the ICD-10 diagnosis codes for COVID-19, because only 
patients assigned such diagnosis codes were examined.
The generalizability of the results of this study is 
improved by the large sample size including all patients 
with a COVID-19 diagnosis code at participating centers 
representative of a country with free health care for all 
residents. Still, coding practices may differ from non- 
infectious diseases departments and other health care set-
tings, or during later stages of the pandemic.
Table 1 Baseline Characteristics of 710 Patients Assigned a First- 
Time ICD-10 Diagnosis Code for COVID-19 at Departments of 
Infectious Diseases in Denmark from February 27 Through 
May 4, 2020













February 27 through March 31, 2020 542 (76)
April 1 through May 4, 2020 168 (24)







Abbreviation: IQR, interquartile ranges.
Table 2 Distribution of Confirmed COVID-19 Among Patients 
Assigned ICD-10 Diagnosis Codes for COVID-19 (DB342A and 
DB972A) at Departments of Infectious Diseases in Denmark
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In conclusion, the overall PPV of ICD-10 diagnosis 
codes for COVID-19 was very high and may be suitable 
for future registry-based prognosis studies of COVID-19.
Abbreviations
CI, Confidence interval; COVID-19, Corona virus disease 
2019; ICD-10, International Classification of Diseases ver-
sions 10; PPV, Positive predictive value; SARS-CoV-2, 
Severe acute respiratory syndrome coronavirus 2.
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